Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
S&S Healthcare Holding EBITDA Margin % Related Terms
S&S Healthcare Holding EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for S&S Healthcare Holding's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4198 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, S&S Healthcare Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
S&S Healthcare Holding EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, S&S Healthcare Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where S&S Healthcare Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
S&S Healthcare Holding (ROCO:4198) has a EBITDA Margin % of -9.21% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on S&S Healthcare Holding and its competitors. According to the industry distribution chart, S&S Healthcare Holding ranks #573 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 70.3%.
Is S&S Healthcare Holding's EBITDA Margin % too high?
S&S Healthcare Holding's current EBITDA Margin % is -9.21%. Based on the distribution chart, S&S Healthcare Holding ranks #573 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, S&S Healthcare Holding has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does S&S Healthcare Holding's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, S&S Healthcare Holding ranks #573 out of 815 companies for EBITDA Margin %. This places S&S Healthcare Holding in the lower half of its industry. The industry median EBITDA Margin % is 7.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on S&S Healthcare Holding and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. S&S Healthcare Holding's current EBITDA Margin % is -9.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S&S Healthcare Holding stock overvalued right now?
Based on GuruFocus' analysis, S&S Healthcare Holding (ROCO:4198) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$23.68, compared to a current price of NT$38.05 — trading 60.7% above its estimated fair value. The current EBITDA Margin % is -9.21%. S&S Healthcare Holding's overall GF Score™ is 54/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For S&S Healthcare Holding (ROCO:4198), the current EBITDA Margin % is -9.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is S&S Healthcare Holding (ROCO:4198) Overvalued in 2026?
Based on GuruFocus' analysis, S&S Healthcare Holding stock appears to be overvalued.
The current stock price of NT$38.05 is trading 60.7% above its estimated GF Value™ of NT$23.68.
GuruFocus considers S&S Healthcare Holding to be Significantly Overvalued.
Key valuation signals for ROCO:4198:
EBITDA Margin %: -9.21%
GF Value™: NT$23.68 vs. price of NT$38.05 (60.7% above fair value)
No single metric tells the full story. See the ROCO:4198 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
S&S Healthcare Holding Ltd, formerly Swissray Global Healthcare Holding Ltd is involved in providing DR systems designed for any application in general radiography. The product divisions of the company cover Swissray DDR systems, Novadaq, and EZ2GO. The main business projects of the company and its subsidiaries are the research and development, manufacturing, sales, and maintenance services of high-end medical equipment and the manufacturing and sales of basic medical equipment.
54GF Score
Get the complete analysis for ROCO:4198
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4198 has been successfully added to your 
